

Individualised treatment for prostate cancer

Thematic Session 09

Sunday, 26 March
10:30 - 12:00

Location: Room Munich, North Hall (Level 1)

Chairs: C.H. Bangma, Rotterdam (NL)
J. N'Dow, Aberdeen (GB)

Aims and objectives of this session

In low-risk prostate cancer various factors may influence the decisions to commit to active surveillance or not. In this session we aim to illustrate the relative contribution of imaging and biomarkers to identify the best individuals to follow an AS protocol. The audience will be able to decide themselves if it is useful, and when, to introduce new diagnostic modalities, or not to start AS at all for a single patient.

10:30 - 10:45

State-of-the-art lecture **Comorbidity assessment and clinical patient profiles in decision making**
P. Mongiat-Artus, Paris (FR)

10:45 - 11:15

Case discussion **Can MRI replace the use of repeat biopsy in active surveillance?**

10:45 - 10:55

Case presenter
M. Valerio, London (GB)

10:55 - 11:05

Pro
C. Moore, London (GB)

11:05 - 11:15

Con
G. Giannarini, Udine (IT)

11:15 - 11:30

State-of-the-art lecture **Using biomarkers in the era of MRI**
Y. Fradet, Quebec (CA)

11:30 - 11:45

State-of-the-art lecture **Genetic markers: Worth the effort and the cost?**
P.J. Boström, Turku (FI)

11:45 - 12:00

Conclusions